MTOR and pneumonitis: Going forward, if a similar targeted combination is tested in another study, a PI3 K-specific targeted agent may be a better choice for evaluating the effect of PI3 K inhibition with less potential for pneumonitis, since the rates of pneumonitis appear to be lower with PI3 K inhibitors than mTOR inhibitors [24, 27].